List of Excipients in Branded Drug CAMPTOSAR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmacia & Upjohn Company LLC	CAMPTOSAR	irinotecan hydrochloride	0009-7529	HYDROCHLORIC ACID
Pharmacia & Upjohn Company LLC	CAMPTOSAR	irinotecan hydrochloride	0009-7529	LACTIC ACID
Pharmacia & Upjohn Company LLC	CAMPTOSAR	irinotecan hydrochloride	0009-7529	SODIUM HYDROXIDE

CAMPTOSAR Excipient Strategy and Commercial Opportunities for Irinotecan Injection

Last updated: August 2, 2026

CAMPTOSAR is the branded irinotecan hydrochloride injection marketed by Pfizer for colorectal cancer. Its commercial protection is largely exhausted: the active ingredient is generic, the original FDA exclusivity period has ended, and irinotecan injection is available from multiple manufacturers. The strongest remaining opportunities are formulation-led rather than molecule-led.

A differentiated product can compete through ready-to-use presentation, reduced preparation risk, improved container compatibility, lower administration waste, pediatric or geriatric dosing flexibility, and delivery systems that alter irinotecan or SN-38 exposure. The core challenge is preserving chemical stability while avoiding excipient-driven toxicity, precipitation, dosing errors, and regulatory complexity.

What is the CAMPTOSAR formulation and which excipients does it contain?

CAMPTOSAR is an intravenous concentrate containing irinotecan hydrochloride trihydrate at 20 mg/mL. The labeled formulation contains sorbitol, lactic acid, and water for injection. The product has an acidic pH of approximately 3.5 [1].

Attribute	CAMPTOSAR profile
Active ingredient	Irinotecan hydrochloride trihydrate
Strength	20 mg/mL
Route	Intravenous infusion after dilution
Primary excipients	Sorbitol, lactic acid, water for injection
Approximate pH	3.5
Administration	Dilution in 5% dextrose or 0.9% sodium chloride
Infusion duration	Typically 30 to 90 minutes
Original NDA	020571
FDA approval	1996
Therapeutic area	Colorectal cancer

Sorbitol functions primarily as a bulking and tonicity-adjusting agent. Lactic acid supports pH control. The acidic environment helps maintain the formulation and limits conditions that could promote degradation or precipitation.

The product is not intended for direct intravenous injection. The concentrate must be diluted before administration, creating opportunities for a manufacturer that can deliver a stable ready-to-use or lower-preparation presentation.

What excipient properties are critical for irinotecan injection?

The commercial formulation target is not simply a replacement for sorbitol and lactic acid. It is a controlled system that must preserve solubility, stability, sterility, extractables performance, and dose accuracy across the labeled shelf life.

pH control

Irinotecan has pH-dependent solubility and stability behavior. A sufficiently acidic environment supports solubility, but excessive acidity can increase handling concerns and may affect container compatibility. A replacement buffer must be evaluated across:

• Assay and related substances
• Visible and subvisible particles
• pH drift
• Precipitation after dilution
• Stability under refrigerated and room-temperature conditions
• Compatibility with infusion bags and administration sets

Phosphate, bicarbonate, and other buffer systems require particular scrutiny because dilution into nonmatching solutions can alter pH and promote precipitation. A low-buffer-capacity system may better preserve compatibility with common infusion fluids, but it may provide less protection against pH drift.

Tonicity and osmolality

Sorbitol contributes to osmolality and may reduce the need for sodium chloride or other tonicity agents. Alternative excipients include sodium chloride, dextrose, mannitol, and selected polyols. Each creates a different regulatory and clinical profile.

Sorbitol is not interchangeable with mannitol. The products have different chemical behavior, osmotic effects, metabolism, and patient-risk considerations. Mannitol can crystallize under some conditions and may create additional container and temperature requirements. Sodium chloride is familiar to hospital pharmacies but changes ionic strength and may affect stability.

Chemical degradation

Irinotecan is converted in vivo to SN-38, the pharmacologically active metabolite. The formulation must control degradation of irinotecan during storage and after dilution. A development program should assess hydrolysis, oxidation, light exposure, and interaction with trace metals.

Relevant excipient screens include:

• Chelators such as edetate derivatives
• Antioxidant systems where justified
• Low-peroxide grades of surfactants
• Container-closure systems with low leachable profiles
• Nitrogen headspace or oxygen-control measures
• Light-protective packaging

Antioxidants are not automatically beneficial. They can create their own impurity profile and may increase regulatory burden. The preferred approach is to establish whether the formulation needs chemical protection before adding a new excipient.

Container compatibility

Irinotecan products may be supplied in glass vials or polymeric containers. A commercial formulation should evaluate:

• Borosilicate glass
• Cyclic olefin polymer and cyclic olefin copolymer
• Polypropylene
• PVC and non-PVC infusion bags
• Elastomeric stoppers
• Silicone oil
• Tubing and administration sets

Sorption, adsorption, extractables, leachables, and surface-mediated degradation can affect actual delivered dose. A ready-to-use product also requires a larger container-closure assessment because the drug remains in contact with the delivery system for a longer period.

What formulation patents could protect a new CAMPTOSAR competitor?

A new irinotecan product cannot rely on broad composition-of-matter protection for irinotecan. The original molecule and conventional injectable formulations are no longer attractive sources of exclusivity. Protection would need to focus on a specific formulation, presentation, manufacturing process, or clinical use.

Formulation patent opportunities

Potential claim categories include:

1. A defined irinotecan concentration and excipient combination.
2. A formulation with a specified pH range and impurity profile.
3. A low-peroxide or low-metal formulation with extended stability.
4. A ready-to-use infusion product with a defined shelf life.
5. A polymeric container that limits sorption or leachables.
6. A formulation that remains particle-free after dilution into specified infusion fluids.
7. A lyophilized irinotecan product with a defined reconstitution profile.
8. A fixed-dose combination with another chemotherapy or targeted agent.
9. A controlled-release or nanoparticle formulation that changes irinotecan or SN-38 exposure.
10. A manufacturing process that reduces degradation products or improves batch consistency.

A patent covering only the use of sorbitol and lactic acid at conventional concentrations would face substantial prior-art risk. Stronger claims would require an unexpected technical effect, such as materially improved stability, reduced preparation error, lower infusion loss, or clinically relevant pharmacokinetic improvement.

Method-of-use patents

Method-of-use claims could target:

• A particular irinotecan dosing schedule
• Combination therapy with a defined biomarker population
• Prevention or management of cholinergic toxicity
• Use in patients with a defined UGT1A1 genotype
• A modified regimen for older or renally impaired patients
• A formulation that supports outpatient administration

Method-of-use protection is commercially valuable only if the indication is enforceable and the product label supports the claimed use. For a generic injectable, label carve-outs may reduce the practical effect of some method patents.

When does CAMPTOSAR lose exclusivity and what is the Orange Book status?

CAMPTOSAR’s principal exclusivity has ended. The product was approved in 1996, and the active ingredient is now available through generic irinotecan hydrochloride injection products [1, 2].

Exclusivity issue	CAMPTOSAR position
New chemical entity exclusivity	Expired
Original FDA approval	1996
Generic competition	Present
Biosimilar pathway	Not applicable
Orange Book relevance	NDA and any listed patents or exclusivity information
Current strategic barrier	Formulation, manufacturing, regulatory, and commercial execution

The Orange Book remains relevant for any currently listed patent claims associated with the NDA, but it does not restore protection to the active ingredient. An applicant developing a conventional irinotecan injection would generally pursue an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence or satisfy the applicable product-specific requirements.

A materially different formulation may require a 505(b)(2) application rather than an ANDA. That route can support a new formulation, concentration, dosage form, or delivery system, but it may require additional clinical or bridging data.

Which companies are challenging CAMPTOSAR, and what is the generic launch risk?

Generic irinotecan manufacturers have already entered the market. The commercial risk is therefore not a future first generic event. It is continuing price erosion, hospital tender competition, and substitution of branded CAMPTOSAR with lower-cost products.

The principal competitor groups are:

• Large generic injectable manufacturers
• Contract manufacturers with oncology sterile-fill capacity
• Regional suppliers serving hospital tenders
• Specialty oncology companies developing liposomal or nanoparticle irinotecan
• Integrated pharmaceutical companies selling irinotecan in combination regimens

Generic launch scenarios

Scenario	Commercial effect
Conventional generic concentrate	Low development risk, high price pressure
Ready-to-use diluted infusion	Higher regulatory and manufacturing burden, potential hospital value
Premixed bag with extended stability	Reduced pharmacy preparation, stronger differentiation
Alternative excipient formulation	Possible intellectual-property protection, requires compatibility data
Liposomal or nanoparticle product	Higher clinical and regulatory cost, potentially different efficacy and safety profile
Fixed-dose combination	Large clinical burden but broader treatment-positioning potential

A conventional ANDA is likely to face the greatest price competition. A differentiated 505(b)(2) product can command a premium only if it reduces pharmacy labor, handling risk, waste, or administration time, or improves clinical outcomes.

What excipient strategy creates the strongest commercial opportunity?

The most practical strategy is a staged platform rather than a single high-risk reformulation.

Phase one: preserve the active formulation and improve presentation

A company can retain the established irinotecan-sorbitol-lactic acid chemistry while developing:

• Ready-to-dilute presentations
• Larger hospital-use containers
• Unit-dose vials
• Barcoded packaging
• Low-overfill containers
• Improved light protection
• Lower-waste packaging
• Pharmacy workflow compatibility

This approach reduces clinical risk and may support an ANDA or a limited 505(b)(2) strategy, depending on the dosage form and labeling differences.

Phase two: develop a differentiated excipient system

The second stage can evaluate:

• Alternative polyols
• Low-ionic-strength tonicity systems
• Chelator-supported formulations
• Oxygen-controlled packaging
• Polymer containers with lower sorption
• Extended post-dilution stability
• Ready-to-use bags

The strongest value proposition is extended stability after dilution. Hospitals may benefit if a product reduces same-day preparation pressure, waste from cancelled treatments, and pharmacy compounding workload. The claim must be supported by validated stability data under realistic storage and administration conditions.

Phase three: change drug disposition

Liposomal, polymeric, albumin-associated, and other nanocarrier systems can alter irinotecan exposure and SN-38 delivery. These products are not simple generic substitutes. They may require clinical trials, new safety characterization, and a 505(b)(2) or full application strategy.

The commercial opportunity is larger, but so is the risk. A carrier system may change neutropenia, diarrhea, hepatic exposure, infusion reactions, and dose scheduling. Excipient selection becomes part of the clinical product rather than a supporting formulation decision.

How does CAMPTOSAR compare with liposomal irinotecan?

Liposomal irinotecan, marketed as ONIVYDE, is a separate product with a different formulation and clinical development history. It is not a biosimilar to CAMPTOSAR and is not interchangeable with conventional irinotecan injection [3].

Attribute	CAMPTOSAR	Liposomal irinotecan
Product type	Conventional irinotecan injection	Liposome-encapsulated irinotecan
Primary market	Conventional colorectal cancer regimens	Defined later-line and combination indications
Regulatory pathway	Original NDA, generic ANDA competition	New-drug development
Excipient role	Solubility, tonicity, pH, stability	Carrier composition, release, biodistribution
Development burden	Low for conventional generic	High
Patent opportunity	Narrow formulation and presentation claims	Carrier, composition, process, and use claims
Substitution	Generic substitution possible	Requires clinical and regulatory differentiation

For a company seeking near-term revenue, improved conventional presentation is more practical. For a company seeking a protected oncology platform, liposomal or controlled-release irinotecan offers greater patent potential but demands substantially greater investment.

What manufacturing and intellectual-property barriers affect irinotecan products?

Sterile manufacturing is the primary execution barrier for conventional products. Key requirements include aseptic processing, validated sterilizing filtration where applicable, particulate control, container-closure integrity, and control of degradation impurities.

The most relevant manufacturing capabilities are:

• Oncology-grade sterile fill-finish
• Low-volume and large-volume parenteral filling
• Polymer container molding or qualified external suppliers
• Controlled oxygen and light exposure
• Automated visual inspection
• Low-bioburden compounding
• Reliable supply of pharmaceutical-grade sorbitol or replacement excipients

Intellectual-property barriers are more limited for a conventional generic. They become more substantial when a product uses a novel carrier, extended-release architecture, specialized container, or defined post-dilution stability profile.

Geographic protection should be assessed separately. U.S. Orange Book listings do not determine patent status in Europe, Japan, China, Canada, or emerging markets. A product with weak U.S. protection may still have commercial value through country-specific formulation, process, or use patents.

What is the revenue exposure and competitive outlook for CAMPTOSAR?

CAMPTOSAR itself has limited branded revenue protection because generic irinotecan is established. Revenue exposure is concentrated in:

• Hospital and oncology clinic purchasing
• Contract and group purchasing organization tenders
• Regional generic pricing
• Availability of sterile manufacturing capacity
• Treatment-volume changes in colorectal cancer
• Use of irinotecan in combination regimens

The highest-value commercial niches are products that reduce total treatment cost rather than merely reduce vial price. A ready-to-use bag can compete on labor, preparation time, medication waste, and handling controls. A differentiated formulation can compete on shelf life and operational reliability.

A conventional generic strategy is likely to produce volume with narrow margins. A protected formulation strategy may produce better margins but requires evidence that the excipient system provides a measurable benefit.

Key Takeaways

• CAMPTOSAR contains irinotecan hydrochloride, sorbitol, lactic acid, and water for injection at 20 mg/mL.
• The active ingredient and conventional injection market are exposed to generic competition.
• The strongest near-term opportunity is a ready-to-use or pharmacy-efficient presentation.
• pH, dilution compatibility, precipitation control, osmolality, container interaction, and post-dilution stability are the core formulation issues.
• New patents should target defined excipient systems, container configurations, stability performance, manufacturing processes, or clinical use.
• A conventional generic is more likely to follow an ANDA route; a materially different formulation may require 505(b)(2) development.
• Biosimilar competition does not apply because irinotecan is a small-molecule drug.
• Liposomal and other nanocarrier products offer greater protection potential but require substantially higher clinical and regulatory investment.
• The commercial case depends on reducing pharmacy labor, waste, preparation risk, or administration burden rather than relying on brand pricing.

FAQs

Can sorbitol be removed from a generic irinotecan formulation?

Yes, but replacement requires comparative formulation, stability, compatibility, and regulatory data. Removing sorbitol may change osmolality, pH behavior, precipitation risk, and container compatibility.

Is a premixed irinotecan infusion eligible for an ANDA?

It may be eligible for an ANDA if it satisfies the applicable pharmaceutical-equivalence and bioequivalence requirements. A materially different dosage form, concentration, or labeling profile may require a 505(b)(2) application.

Can a new excipient create market exclusivity for irinotecan?

A new excipient alone does not guarantee exclusivity. Protection is stronger when the excipient produces a defined and unexpected technical result, such as extended stability, reduced degradation, or improved dilution compatibility.

Does irinotecan have biosimilar competition?

No. Biosimilars apply to biological products. Irinotecan is a chemically synthesized small-molecule drug and is subject to generic-drug competition.

What is the most attractive hospital opportunity for an irinotecan reformulation?

A stable, ready-to-use infusion product with low preparation burden and reduced waste is the most practical opportunity. Its value must exceed the price premium created by sterile manufacturing and specialized packaging.

References

1. U.S. Food and Drug Administration. (2024). CAMPTOSAR (irinotecan hydrochloride) injection prescribing information. Pfizer Laboratories. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
3. U.S. Food and Drug Administration. (2024). ONIVYDE (irinotecan liposome injection) prescribing information. Ipsen Biopharmaceuticals, Inc. https://www.accessdata.fda.gov